Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...
There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...
That amyloid subtype was described as a “toxic oligomer” — soluble in the fluid that bathes the brain, unlike the sticky plaques commonly associated with Alzheimer’s. The study became ...
The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.
The study used gold-standard autopsy confirmation to show that a blood test for Alzheimer's disease accurately detected ...
Alzheimer’s disease affects more than 30m people worldwide, mostly the elderly. After the age of 65, the chance of developing ...
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.
New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
The test could help identify one key Alzheimer's biomarker, tau protein, before it shows up in brain. Here's what experts say ...
Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into ...
News Medical on MSN3d
Breakthrough discovery on tau protein opens new paths for Alzheimer’s drug developmentA complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback